All In Biotech

Drug Trial Radar · NCT07253285

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Efficacy, Safety and Pharmacokinetics of Cagrilintide s.c. 2.4 mg as Monotherapy and in Combination With Semaglutide s.c. 2.4 mg (CagriSema) Once Weekly for Weight Management in Chidren and Adolescents With Overweight or Obesity

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 460 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

460

Planned (sponsor's estimate)

Start

Jan 8, 2026

Primary completion

Mar 20, 2030

Study completion Sep 20, 2033

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Nov 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 8 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to adolescents and adults) or placebo (a placebo looks like the treatment being tested, but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants who get semaglutide in the main study will not take part in the extension study. If participants take part in the extension study, they will get either CagriSema or cagrilintide in this part of the study. Like all drugs, the study drugs may have side effects. The total time participants will be in the main study is about 1 year and 6 months. If participants take part in the extension study, the total time is about 4 years and 10 months.

Conditions

  • Overweight
  • Obesity

Interventions

  • CagrilintideDrug

    Participants will receive cagrilintide subcutaneously.

  • SemaglutideDrug

    Participants will receive semaglutide subcutaneously.

  • Placebo cagrilintideDrug

    Participants will receive placebo matched to cagrilintide subcutaneously.

  • Placebo semaglutideDrug

    Participants will receive placebo matched to semaglutide subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change in body mass index (BMI)Time frame: Baseline (week 0), week 68

Locations

121 sites in 26 countries. Site status is shown where the registry gives one.

  • Neighborhood Healthcare

    Escondido, California · Recruiting

  • Encore Medical Research LLC

    Hollywood, Florida · Recruiting

  • Jacksonville Ctr for Clin Res

    Jacksonville, Florida · Recruiting

  • Encore Medical Research of Weston

    Weston, Florida · Recruiting

  • Children's Healthcare Atlanta

    Atlanta, Georgia · Recruiting

  • Columbus Research Foundation

    Columbus, Georgia · Recruiting

  • Accel Research Sites-NeuroStudies

    Decatur, Georgia · Recruiting

  • Eastside Bariatric and Gen Surg

    Snellville, Georgia · Recruiting

  • Solaris Clinical Research

    Meridian, Idaho · Recruiting

  • IU Health - Riley Physicians Endo-Diab

    Indianapolis, Indiana · Recruiting

  • Cotton O'Neil Clinical Research Center

    Topeka, Kansas · Recruiting

  • Pennington Biomed Res Ctr

    Baton Rouge, Louisiana · Recruiting

  • Barry J. Reiner, MD LLC

    Baltimore, Maryland · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Synexus Clinical Research US-MN

    Richfield, Minnesota · Recruiting

  • UBMD Physicians Group - Pediatrics - Conventus

    Buffalo, New York · Not yet recruiting

  • SUNY Upstate Medical Univ - Syracuse

    Syracuse, New York · Recruiting

  • Advantage Clinical Trials

    The Bronx, New York · Not yet recruiting

  • Valley Weight Loss Clinic

    Fargo, North Dakota · Recruiting

  • Centricity Research - Ohio

    Columbus, Ohio · Recruiting

  • PriMed Clinical Research

    Dayton, Ohio · Recruiting

  • Children's Physicians OU

    Oklahoma City, Oklahoma · Not yet recruiting

  • UPMC Child Hosp-Pittsburgh

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Prisma Health-Ped Endo

    Greenville, South Carolina · Not yet recruiting

  • Coastal Carolina Research Ctr

    North Charleston, South Carolina · Recruiting

  • Monument Health Clinical Rsrch

    Rapid City, South Dakota · Not yet recruiting

  • LifeDoc Health

    Memphis, Tennessee · Recruiting

  • DM Clinical

    Houston, Texas · Recruiting

  • DM Clinical

    San Antonio, Texas · Not yet recruiting

  • The Texas Liver Institute

    San Antonio, Texas · Recruiting

  • Pinnacle Clinical Research

    San Antonio, Texas · Recruiting

  • Consano Clin Res-Shavano Park

    Shavano Park, Texas · Recruiting

  • Texas Valley Clinical Research

    Weslaco, Texas · Recruiting

  • AMR Clinical

    Layton, Utah · Recruiting

  • The Children's Hospital at Westmead - Clinical Research Centre

    Westmead, New South Wales, Australia · Recruiting

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia · Recruiting

  • Perth Children's Hospital

    Nedlands, Western Australia, Australia · Recruiting

  • Universitätsklinik Kinder-Jugendheilkunde Innsbruck

    Innsbruck, Austria · Recruiting

  • Universitätsklinik für Kinder und Jugendheilkunde Haus E

    Salzburg, Austria · Recruiting

  • UZ Brussel - Universitair Ziekenhuis Brussel

    Brussels, Belgium · Recruiting

Showing 40 of 121 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.